Quick answer
Royalty Pharma plc (RPRX) reported revenue of $2.38B and net income of $770.9M for the fiscal year ended 2025-12-31, up 5.1% from $2.26B the year before, per its 10-K filed with the SEC on 2026-02-11. Long-term debt stood at $8.95B.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $2.38B | $770.9M | $8.95B |
| 2024 (FY ending 2024-12-31) | $2.26B | $859.0M | $7.61B |
| 2023 (FY ending 2023-12-31) | $2.35B | $1.13B | $6.14B |
| 2022 (FY ending 2022-12-31) | $2.24B | $42.8M | $7.12B |
| 2021 (FY ending 2021-12-31) | $2.29B | $619.7M | $7.10B |
| 2020 (FY ending 2020-12-31) | $2.12B | $975.0M | $5.82B |
| 2019 (FY ending 2019-12-31) | $1.81B | $2.35B | $5.96B |
| 2018 (FY ending 2018-12-31) | $1.79B | $1.38B | — |
Related
- ROP revenue, net income and debt history (Roper Technologies, Inc.)
- ROST revenue, net income and debt history (Ross Stores, Inc.)
- RPM revenue, net income and debt history (RPM International Inc.)
- RRC revenue, net income and debt history (Range Resources Corp)
- RRX revenue, net income and debt history (Regal Rexnord Corp)
- RS revenue, net income and debt history (Reliance, Inc.)
- RSG revenue, net income and debt history (Republic Services, Inc.)
- RTX revenue, net income and debt history (Rtx Corporation)
Last updated 2026-10-16. Data only, not financial or tax advice.